ArticleClinical pharmacology and therapeutics2025

A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients.

Donald Irby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.